GastroAGI
@gastroagi.bsky.social
Empowering clinicians & trainees with expert GI & liver updates, clinical pearls & trending research.
🔗 https://gastroagi.com
🔗 https://gastroagi.com
Pinned
GastroAGI | January 2026 Updates
Explore the latest high-impact research in gastroenterology and hepatology from leading journals. Log in, click Trending Topics, and stay updated with January 2026 insights.
🧠 gastroagi.com
Explore the latest high-impact research in gastroenterology and hepatology from leading journals. Log in, click Trending Topics, and stay updated with January 2026 insights.
🧠 gastroagi.com
An SVM-based ML model predicts postoperative recurrence in ESCC. Using clinical, lab, and pathologic factors, the SVM6+8 model achieved high sensitivity. A nomogram estimates 1-, 3-, 5-yr DFS, enabling risk stratification and personalized follow-up/adjuvant therapy.
#gastroenterology
#gastroenterology
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 15, 2026 at 11:58 AM
An SVM-based ML model predicts postoperative recurrence in ESCC. Using clinical, lab, and pathologic factors, the SVM6+8 model achieved high sensitivity. A nomogram estimates 1-, 3-, 5-yr DFS, enabling risk stratification and personalized follow-up/adjuvant therapy.
#gastroenterology
#gastroenterology
📘 Chicago Classification v4.0 tightens HRM interpretation with mandatory clinical correlation. Supine + upright swallows required. EGJOO needs ↑IRP in both + abnormal confirmatory test. Achalasia, DES, Jackhammer require symptoms + supportive tests.
🧠 gastroagi.com/chat
#gasteroenterology
🧠 gastroagi.com/chat
#gasteroenterology
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 15, 2026 at 11:56 AM
📘 Chicago Classification v4.0 tightens HRM interpretation with mandatory clinical correlation. Supine + upright swallows required. EGJOO needs ↑IRP in both + abnormal confirmatory test. Achalasia, DES, Jackhammer require symptoms + supportive tests.
🧠 gastroagi.com/chat
#gasteroenterology
🧠 gastroagi.com/chat
#gasteroenterology
⚠ Ultra-processed foods (UPFs) & early death: Higher UPF intake is linked to increased mortality. Countries with very high UPF consumption show more premature deaths. Experts urge taxes, clearer labeling, and better access to healthy foods.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 15, 2026 at 11:55 AM
⚠ Ultra-processed foods (UPFs) & early death: Higher UPF intake is linked to increased mortality. Countries with very high UPF consumption show more premature deaths. Experts urge taxes, clearer labeling, and better access to healthy foods.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🔪 Two-stage hepatectomy (TSH): option for initially unresectable colorectal liver mets. 🩺 Stage 1: debulk tumors + liver regeneration. 🩸 Stage 2: resect residual disease after FLR hypertrophy. Enables long-term survival, potential cure.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 15, 2026 at 11:54 AM
🔪 Two-stage hepatectomy (TSH): option for initially unresectable colorectal liver mets. 🩺 Stage 1: debulk tumors + liver regeneration. 🩸 Stage 2: resect residual disease after FLR hypertrophy. Enables long-term survival, potential cure.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
Autoantibodies in MASLD (ANA, ASMA) are common and signal worse prognosis: higher risk of liver decompensation and mortality. They mark immune activation, predict progression to cACLD, and support risk stratification and closer monitoring. #GastroAGI #MASLD #Liver
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 15, 2026 at 11:52 AM
Autoantibodies in MASLD (ANA, ASMA) are common and signal worse prognosis: higher risk of liver decompensation and mortality. They mark immune activation, predict progression to cACLD, and support risk stratification and closer monitoring. #GastroAGI #MASLD #Liver
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
📏 FLIP panometry—Dallas Consensus: Experts standardized 40 guidelines to reduce variability. Normal FLIP reliably rules out major motility disorders. ↓EGJ opening with weak contractions suggests EGJ outflow obstruction. Major step toward uniform global practice.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:59 PM
📏 FLIP panometry—Dallas Consensus: Experts standardized 40 guidelines to reduce variability. Normal FLIP reliably rules out major motility disorders. ↓EGJ opening with weak contractions suggests EGJ outflow obstruction. Major step toward uniform global practice.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🔥 HbA1c & infected pancreatic necrosis: HbA1c ≥6.5% confers ~4× higher IPN risk in acute necrotizing pancreatitis. Hyperglycemia drives immune dysfunction, bacterial translocation & inflammation. Early HbA1c testing and strict glucose control are key.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:58 PM
🔥 HbA1c & infected pancreatic necrosis: HbA1c ≥6.5% confers ~4× higher IPN risk in acute necrotizing pancreatitis. Hyperglycemia drives immune dysfunction, bacterial translocation & inflammation. Early HbA1c testing and strict glucose control are key.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🔆 Radiotherapy in HCC: Y90 vs SBRT—Y90 delivers heterogeneous microsphere radiation (2–3 mm, days; t½ ~64 h), reducing biologic effect per Gy. SBRT gives uniform, precise high-dose in minutes. ~400 Gy Y90 ≈ 40–50 Gy SBRT.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:58 PM
🔆 Radiotherapy in HCC: Y90 vs SBRT—Y90 delivers heterogeneous microsphere radiation (2–3 mm, days; t½ ~64 h), reducing biologic effect per Gy. SBRT gives uniform, precise high-dose in minutes. ~400 Gy Y90 ≈ 40–50 Gy SBRT.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🧬 Chronic pancreatitis markedly increases pancreatic cancer risk (~8×), higher than acute pancreatitis. Risk is greatest for PDAC and IPMN. CP patients should be considered high-risk, supporting targeted screening strategies.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:58 PM
🧬 Chronic pancreatitis markedly increases pancreatic cancer risk (~8×), higher than acute pancreatitis. Risk is greatest for PDAC and IPMN. CP patients should be considered high-risk, supporting targeted screening strategies.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🫀 LT for CRLM: Multicenter data show strong survival (1–5y OS 94/73/55%). Women had ~4× higher mortality, linked to right-sided tumors, KRAS mutations & ↑ liver recurrence. Poor prognostic factors: CEA >80, large nodules, pN2. Sex-aware selection needed.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:58 PM
🫀 LT for CRLM: Multicenter data show strong survival (1–5y OS 94/73/55%). Women had ~4× higher mortality, linked to right-sided tumors, KRAS mutations & ↑ liver recurrence. Poor prognostic factors: CEA >80, large nodules, pN2. Sex-aware selection needed.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🌬️ Breath biopsy in cirrhosis: Noninvasive VOC analysis. Seven VOCs (e.g., limonene, 2-pentanone, indole) detected cirrhosis with AUC 0.95. Reflects impaired CYP/detox pathways & gut–liver axis. VOC profiles correlate with Child-Pugh stage—promising for early detection & staging
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:57 PM
🌬️ Breath biopsy in cirrhosis: Noninvasive VOC analysis. Seven VOCs (e.g., limonene, 2-pentanone, indole) detected cirrhosis with AUC 0.95. Reflects impaired CYP/detox pathways & gut–liver axis. VOC profiles correlate with Child-Pugh stage—promising for early detection & staging
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
⚡🧠 Translumbosacral neuromodulation (TNT), ACG 2025: Reduced weekly fecal incontinence episodes (7.7→2.8; 8.3→3.5, dose-dependent). Improved pudendal nerve function suggests neural recovery. Promising but still investigational.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:57 PM
⚡🧠 Translumbosacral neuromodulation (TNT), ACG 2025: Reduced weekly fecal incontinence episodes (7.7→2.8; 8.3→3.5, dose-dependent). Improved pudendal nerve function suggests neural recovery. Promising but still investigational.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🧬 Why immunotherapy fails in CRC: TGF-β blocks T-cell tumor entry; intratumoral macrophage osteopontin suppresses T-cell function → immune-cold tumors resistant to PD-1/PD-L1. Combining TGF-β or osteopontin blockade with ICIs shows preclinical promise.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:57 PM
🧬 Why immunotherapy fails in CRC: TGF-β blocks T-cell tumor entry; intratumoral macrophage osteopontin suppresses T-cell function → immune-cold tumors resistant to PD-1/PD-L1. Combining TGF-β or osteopontin blockade with ICIs shows preclinical promise.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
⚠️ Anastomotic leak after ESCC esophagectomy: Incidence 21.5%. Risks: older age, cervical anastomosis, anemia, NLR >14.6, poor nutrition. Predictive nomogram AUC 0.87. Early CT/POD7 imaging, biomarker monitoring, and nutritional optimization improve outcomes.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:56 PM
⚠️ Anastomotic leak after ESCC esophagectomy: Incidence 21.5%. Risks: older age, cervical anastomosis, anemia, NLR >14.6, poor nutrition. Predictive nomogram AUC 0.87. Early CT/POD7 imaging, biomarker monitoring, and nutritional optimization improve outcomes.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🚭 Smoking & MASLD: Active smoking raises risk 30–41%, dose-dependent (≥20 pack-yrs ↑32%); passive smoke ↑13%. Mechanisms: oxidative stress, insulin resistance, inflammation, gut–liver axis disruption. Quitting >10 yrs lowers risk to nonsmoker levels.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:56 PM
🚭 Smoking & MASLD: Active smoking raises risk 30–41%, dose-dependent (≥20 pack-yrs ↑32%); passive smoke ↑13%. Mechanisms: oxidative stress, insulin resistance, inflammation, gut–liver axis disruption. Quitting >10 yrs lowers risk to nonsmoker levels.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🦠 Blown-out myotomy (BOM) in achalasia: Failed prior myotomy → recurrent dysphagia, chest pain, poor emptying. New data show POEM is a safe, effective salvage option with 85.7% success at 2 yrs, even with altered anatomy, restoring swallowing and QoL.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:56 PM
🦠 Blown-out myotomy (BOM) in achalasia: Failed prior myotomy → recurrent dysphagia, chest pain, poor emptying. New data show POEM is a safe, effective salvage option with 85.7% success at 2 yrs, even with altered anatomy, restoring swallowing and QoL.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🦠 Gut–lung crosstalk in sepsis: Dysbiosis + barrier failure → LPS translocation, lung inflammation, NETs, ALI/ARDS. Immune shift to glycolysis (HIF-1α), ROS/mtDNA, gut metabolites worsen injury. Restoring the axis (probiotics/FMT, vagal activation, immunometabolic profiling) may improve outcomes.
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:55 PM
🦠 Gut–lung crosstalk in sepsis: Dysbiosis + barrier failure → LPS translocation, lung inflammation, NETs, ALI/ARDS. Immune shift to glycolysis (HIF-1α), ROS/mtDNA, gut metabolites worsen injury. Restoring the axis (probiotics/FMT, vagal activation, immunometabolic profiling) may improve outcomes.
♻️ Second-line *H. pylori* therapy: Do not reuse clarithromycin or levofloxacin. Select rescue regimens based on local resistance or susceptibility testing. Options include 10–14 d bismuth quadruple therapy or guided levofloxacin-based quadruple therapy.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:55 PM
♻️ Second-line *H. pylori* therapy: Do not reuse clarithromycin or levofloxacin. Select rescue regimens based on local resistance or susceptibility testing. Options include 10–14 d bismuth quadruple therapy or guided levofloxacin-based quadruple therapy.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
First-line *H. pylori* therapy: Bismuth quadruple therapy preferred empiric regimen, esp where clarithro resistance is high—PPI + tetracycline + metronidazole + bismuth. PCAB (vonoprazan)–based regimens are effective alternatives. Avoid levofloxacin first line.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:54 PM
First-line *H. pylori* therapy: Bismuth quadruple therapy preferred empiric regimen, esp where clarithro resistance is high—PPI + tetracycline + metronidazole + bismuth. PCAB (vonoprazan)–based regimens are effective alternatives. Avoid levofloxacin first line.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🧬 “Big Bang” in bowel cancer: Early tumor event fixes lifelong immune evasion via loss/silencing of immune-recognition genes & neoantigens. Explains poor ICI response (~15%). Targeting epigenetics may restore immunogenicity, improve vaccines & expand ICI benefit.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:54 PM
🧬 “Big Bang” in bowel cancer: Early tumor event fixes lifelong immune evasion via loss/silencing of immune-recognition genes & neoantigens. Explains poor ICI response (~15%). Targeting epigenetics may restore immunogenicity, improve vaccines & expand ICI benefit.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
Genetic testing in familial gastric cancer: Combine germline testing with *H. pylori* assessment to refine risk. Key genes: CDH1, CTNNA1, BRCA1/2, PALB2, MLH1, MSH2. Test early-onset (<40y) cases and syndromes (HDGC, Lynch).
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:54 PM
Genetic testing in familial gastric cancer: Combine germline testing with *H. pylori* assessment to refine risk. Key genes: CDH1, CTNNA1, BRCA1/2, PALB2, MLH1, MSH2. Test early-onset (<40y) cases and syndromes (HDGC, Lynch).
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
H. pylori population screening: Prefer noninvasive tests—¹³C-UBT or monoclonal HpSA. Hold PPIs/PCABs 2 wks and antibiotics/bismuth 4 wks before testing. Choice guided by cost, logistics, and patient comfort.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:54 PM
H. pylori population screening: Prefer noninvasive tests—¹³C-UBT or monoclonal HpSA. Hold PPIs/PCABs 2 wks and antibiotics/bismuth 4 wks before testing. Choice guided by cost, logistics, and patient comfort.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
🦠 H. pylori & gastric cancer: Chinese cohort showed strong association—HR 5.59 for non-cardia GC, HR 2.17 for cardia GC. CGC risk varies by region & GERD/obesity/smoking. In Taiwan, most GC & MALT linked to H. pylori; eradication induces 60–70% MALT remission.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:53 PM
🦠 H. pylori & gastric cancer: Chinese cohort showed strong association—HR 5.59 for non-cardia GC, HR 2.17 for cardia GC. CGC risk varies by region & GERD/obesity/smoking. In Taiwan, most GC & MALT linked to H. pylori; eradication induces 60–70% MALT remission.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
💊 Enfortumab vedotin (EV), a Nectin-4–targeted ADC: EV-202 showed limited activity in GEA (ORR 9.5%) but meaningful responses in ESCC (ORR 18.2%). Manageable safety; rash & hyperglycemia common. EV may have a salvage role in ESCC; limited value in GEA.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:53 PM
💊 Enfortumab vedotin (EV), a Nectin-4–targeted ADC: EV-202 showed limited activity in GEA (ORR 9.5%) but meaningful responses in ESCC (ORR 18.2%). Manageable safety; rash & hyperglycemia common. EV may have a salvage role in ESCC; limited value in GEA.
🧠 gastroagi.com/chat
🧠 gastroagi.com/chat
☕ HCC chemoprevention: HBV vaccination ↓ risk 80–90%; HBV/HCV antivirals ~70%. Statins & aspirin cut incidence ~30–40% via anti-inflammatory/anti-fibrotic effects. GLP-1RAs & SGLT2i promising in MASLD. Coffee & Mediterranean diet protective. Best strategy: viral control + metabolic management.
GastroAGI - AI Chat for Gastroenterology Students
Ask AI-powered questions about gastroenterology and enhance your academic learning.
gastroagi.com
January 13, 2026 at 12:52 PM
☕ HCC chemoprevention: HBV vaccination ↓ risk 80–90%; HBV/HCV antivirals ~70%. Statins & aspirin cut incidence ~30–40% via anti-inflammatory/anti-fibrotic effects. GLP-1RAs & SGLT2i promising in MASLD. Coffee & Mediterranean diet protective. Best strategy: viral control + metabolic management.